Clinical Trial Update: Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erythropoietin for depressive symptoms and neurocognitive deficits in mood disorders; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Lars Vedel Kessing, professor, MD, DMSc. | Conditions: Mood Disorders | Phase 2 | Status: COMPLETED